Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: A specific role for antibodies against the membrane-proximal external region of gp41

Journal of Virology

Volumn 83, Issue 15, 2009, Pages 7397-7410

  Perez, Lautaro G ^a   Costa, Matthew R ^a   Todd, Christopher A ^a   Haynes, Barton F ^a   Montefiori, David C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; FC RECEPTOR; FC RECEPTOR I; FC RECEPTOR IIA; FC RECEPTOR IIB; FC RECEPTOR IIIA; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 4E10; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; GENETIC TRANSDUCTION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; CELL LINE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G; MOLECULAR SEQUENCE DATA; RECEPTORS, IGG; SEQUENCE ALIGNMENT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 67650882680     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00656-09     Document Type: Article

References (110)

1. Alam, S. M., M. McAdams, D. Boren, M. Rak, R. M. Scearce, F. Gao, Z. T. Camacho, D. Gewirth, G. Kelsoe, P. Chen, and B. F. Haynes. 2007. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J. Immunol. 178:4424-4435.
2. Baravalle, G., M. Brabec, L. Snyers, D. Blaas, and R. Fuchs. 2004. Human rhinovirus type 2-antibody complexes enter and infect cells via Fcγ receptor IIB1. J. Virol. 78:2729-2737.
3. Barbato, G., E. Bianchi, P. Ingallinella, W. H. Hurni, M. D. Miller, G. Ciliberto, R. Cortese, R. Bazzo, J. W. Shiver, and A. Pessi. 2003. Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion. J. Mol. Biol. 330:1101-1115.
4. Barnes, N., A. L. Gavin, P. S. Tan, P. Mottram, F. Koentgen, and P. M. Hogarth. 2002. FcγRI-deficient mice show multiple alterations to inflammatory and immune responses. Immunity 16:379-389.
5. Baum, L. L., K. J. Cassutt, K. Knigge, R. Khattri, J. Margolick, C. Rinaldo, C. A. Kleeberger, P. Nishanian, D. R. Henrard, and J. Phair. 1996. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J. Immunol. 157:2168-2173.
6. Bevaart, L., M. J. H. Jansen, M. J. van Vugt, J. S. Verbeek, J. G. J. van de Winkel, and J. H. W. Leusen. 2006. The high-affinity IgG receptor, FcγRI, plays a central role in antibody therapy of experimental melanoma. Cancer Res. 66:1261-1264.
7. Binley, J. M., E. A. Lybarger, E. T. Crooks, M. S. Seaman, E. Gray, K. L. Davis, J. M. Decker, D. Wycuff, L. Harris, N. Hawkins, B. Wood, C. Nathe, D. Richman, G. D. Tomaras, F. Bibollet-Ruche, J. E. Robinson, L. Morris, G. M. Shaw, D. C. Montefiori, and J. R. Mascola. 2008. Profiling the specificity of neutralizing antibodies in a large panel of human immunode-ficiency virus type 1 plasmas from subtype B and C chronic infections. J. Virol. 82:11651-11668.
8. Blish, C. A., R. Nedellec, K. Mandaliya, D. E. Mosier, and J. Overbaugh. 2007. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS 21:693-702.
9. Brown, A., H. Zhang, P. Lopez, C. A. Pardo, and S. Gartner. 2006. In vitro modeling of the HIV-macrophage reservoir. J. Leukoc. Biol. 80:1127-1135.
10. Bruhns, P., B. Iannascoli, P. England, D. A. Mancardi, N. Fernandez, S. Jorieux, and M. Daëron. 2009. Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood 113: 3716-3725.
11. Brunel, F. M., M. B. Zwick, R. M. F. Cardoso, J. D. Nelson, I. A. Wilson, D. R. Burton, and P. E. Dawson. 2006. Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody. J. Virol. 80:1680-1687.
12. Byrne, G. I., and J. W. Moulder. 1978. Parasite-specific phagocytosis of Chlamydia psittaci and Chlamydia trachomatis by L and HeLa cells. Infect. Immun. 19:598-606.
13. Calarese, D. A., C. N. Scanlan, M. B. Zwick, S. Deechongkit, Y. Mimura, R. Kunert, P. Zhu, M. R. Wormald, R. L. Stanfield, K. H. Roux, J. W. Kelly, P. M. Rudd, R. A. Dwek, H. Katinger, D. R. Burton, and I. A. Wilson. 2003. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300:2065-2071.
14. Cardoso, R. M. F., M. B. Zwick, R. L. Stanfield, R. Kunert, J. M. Binley, H. Kaninger, D. R. Burton, and I. A. Wilson. 2005. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22:163-173.
15. Cassol, E., M. Alfano, P. Biswas, and G. Poli. 2006. Monocyte-derived macrophages and myeloid cell lines as targets of HIV-1 replication and persistence. J. Leukoc. Biol. 80:1018-1030.
16. Cavacini, L., C. Emes, A. Wisnewski, J. Power, G. Lewis, D. Montefiori, and M. Posner. 1998. Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. AIDS Res. Hum. Retroviruses. 14:1271-1280.
17. Chan, D. C., and P. S. Kim. 1998. HIV entry and its inhibition. Cell 93:681-684.
18. Choudhry, V., M.-Y. Zhang, I. Harris, I. A. Sidorov, B. Vu, A. S. Dimitrov, T. Fouts, and D. S. Dimitrov. 2006. Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. Biochem. Biophys. Res. Commun. 348:1107-1115.
19. Connor, R. I., N. B. Dinces, A. L. Howell, J. L. Romet-Lemonne, J. L. Pasquali, and M. W. Fanger. 1991. Fc receptors for IgG (FcγRs) on human monocytes and macrophages are not infectivity receptors for human immunodeficiency virus type 1 (HIV-1): studies using bispecific antibodies to target HIV-1 to various myeloid cell surface molecules, including the FcγR. Proc. Natl. Acad. Sci. USA 88:9593-9597.
20. Dall'Acqua, W. F., K. E. Cook, M. M. Damschroder, R. M. Woods, and H. Wu. 2006. Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J. Immunol. 177:1129-1138.
21. David, A., A. Saez-Cirion, P. Versmisse, O. Malbec, B. Iannascoli, F. Herschke, M. Lucas, F. Barre-Sinoussi, J.-F. Mouscadet, M. Daeron, and G. Pancino. 2006. The engagement of activating FcγRs inhibits primate lentivirus replication in human macrophages. J. Immunol. 177:6291-6300.
22. Desjarlais, J. R., G. A. Lazar, E. A. Zhukovsky, and S. Y. Chu. 2007. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov. Today 12:898-910.
23. Dijstelbloem, H. M., C. G. M. Kallenberg, and J. G. J. van de Winkel. 2001. Inflammation in autoimmunity: receptors for IgG revisited. Trends Immunol. 22:510-516.
24. -plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood 98:2574-2576.
25. Ernst, L. K., A. M. Duchemin, and C. L. Anderson. 1993. Association of the high-affinity receptor for IgG (FcγRI) with the gamma subunit of the IgE receptor. Proc. Natl. Acad. Sci. USA 90:6023-6027.
26. Fernandez, N., M. Renedo, C. Garcia-Rodriguez, and M. Sanchez Crespo. 2002. Activation of monocytic cells through Fcγ receptors induces the expression of macrophage-inflammatory proteins MIP-1α, MIP-1β and RANTES. J. Immunol. 169:3321-3328.
27. Forthal, D. N., P. B. Gilbert, G. Landucci, and T. Phan. 2007. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J. Immunol. 178:6596-6603.
28. Forthal, D. N., G. Landucci, J. Bream, L. P. Jacobson, T. B. Phan, and B. Montoya. 2007. FcγRIIa genotype predicts progression of HIV infection. J. Immunol. 179:7916-7923.
29. Forthall, D. N., G. Landucci, and E. S. Daar. 2001. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural killer effector cells. J. Virol. 75:6953-6961.
30. Frey, G., H. Peng, S. Rits-Volloch, M. Morelli, Y. Cheng, and B. Chen. 2008. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc. Natl. Acad. Sci. USA 105:3739-3744.
31. Galvin, S. R., and M. S. Cohen. 2006. Genital tract reservoirs. Curr. Opin. HIV AIDS 1:162-166.
32. Ghigo, E., C. Capo, M. Aurouze, C. H. Tung, J. P. Gorvel, D. Raoulty, and J. L. Mege. 2002. Survival of Tropheryma whipplei, the agent of Whipple's disease, requires phagosome acidification. Infect. Immun. 70:1501-1506.
33. Goncalvez, A. P., R. E. Engle, M. St. Claire, R. H. Purcell, and C.-J. Lai. 2007. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc. Natl. Acad. Sci. USA 104:9422-9427.
34. Gorny, M. K., V. Gianakakos, S. Sharpe, and S. Zolla-Pazner. 1989. Generation of human monoclonal antibodies to human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 86:1624-1628.
35. Gosselin, E. J., K. Wardwell, D. R. Gosselin, N. Alter, J. L. Fisher, and P. M. Guyre. 1992. Enhanced antigen presentation using human Fc gamma receptor (monocyte/macrophage)-specific immunogens. J. Immunol. 149: 3477-3481.
36. Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodies directed against the N-terminal helical repeat of gp41. J. Virol. 82:10032-10041.
37. Guzmán-Verri, C., E. Chaves-Olarte, C. von Eichel-Streiber, I. López-Goňi, M. Thelestam, S. Arvidson, J-P Gorvel, and E. Moreno. 2001. GTPases of the Rho subfamily are required for Brucella abortus internalization of nonprofessional phagocytes. J. Biol. Chem. 276:44435-44443.
38. Hager-Braun, C., H. Katinger, and K. B. Tomer. 2006. The HIV-neutralizing monoclonal antibody 4E10 recognizes N-terminal sequences on the native antigen. J. Immunol. 176:7471-7481.
39. Haynes, B. F., J. Fleming, E. W. St Clair, H. Katinger, G. Stiegler, R. Kunert, J. Robinson, R. M. Scearce, K. Plonk, H. F. Staats, T. L. Ortel, H. X. Liao, and S. M. Alam. 2005. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308:1906-1908.
40. Haynes, B. F., M. A. Moody, L. Verkoczy, G. Kelsoe, and S. M. Alam. 2005. Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum. Antibodies 14:59-67.
41. Heijnen, I. A., M. J. van Vugt, N. A. Fanger, R. F. Graziano, T. P. de Wit, F. M. Hofhuis, P. M. Guyre, P. J. Capel, J. S. Verbeek, and J. G. van de Winkel. 1996. Antigen targeting to myeloid-specific human Fcγ RI/CD64 triggers enhanced antibody responses in transgenic mice. J. Clin. Investig. 97:331-338.
42. Hessell, A. J., L. Hangartner, M. Hunter, C. E. G. Havenith, F. J. Beurskens, J. M. Bakker, C. M. S. Lanigan, G. Landucci, D. N. Forthal, P. W. H. I. Parren, P. A. Marx, and D. R. Burton. 2007. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449:101-104.
43. Hezareh, M., A. J. Hessell, R. C. Jensen, J. G. J. van de Winkel, and P. W. H. I. Parren. 2001. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J. Virol. 75:12161-12168.
44. Holl, V., S. Hemmerter, R. Burrer, S. Schmidt, A. Bohbot, A.-M. Aubertin, and C. Moog. 2004. Involvement of FcγR I (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages. J. Immunol. 173:6274-6283.
45. Holl, V., M. Peressin, T. Decoville, S. Schmidt, S. Zolla-Pazner, A.-M. Aubertin, and C. Moog. 2006. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J. Virol. 80:6177-6181.
46. Holl, V., M. Peressin, S. Schmidt, T. Decoville, S. Zolla-Pazner, A.-M. Aubertin, and C. Moog. 2006. Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation. Blood 107:4466-4474.
47. Homsy, J., M. Meyer, M. Tateno, S. Clarkson, and J. A. Levy. 1989. The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. Science 244:1357-1360.
48. Huber, V. C., J. M. Lynch, D. J. Bucher, J. Le, and D. W. Metzger. 2001. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J. Immunol. 166:7381-7388.
49. Hulett, M. D., and P. M. Hogarth. 1994. Molecular basis of Fc receptor function. Adv. Immunol. 57:1-127.
50. Ioan-Facsinay, A., S. J. de Kimpe, S. M. M. Hellwig, P. L. van Lent, F. M. A. Hofhuis, H. H. van Ojik, C. Sedlik, S. A. da Silveira, J. Gerber, Y. F. de Jong, R. Roozendaal, L. A. Aarden, W. B. van den Berg, T. Saito, D. Mosser, S. Amigorena, S. Izui, G. J. B. van Ommen, M. van Vugt, J. G. J. van de Winkel, and J. S. Verbeek. 2002. FcγRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity 16:391-402.
51. Jouault, T., F. Chapuis, R. Olivier, C. Parravicini, E. Bahraoui, and J.-C. Gluckman. 1989. HIV infection of monocytic cells: role of antibody-mediated virus binding to Fcγ receptors. AIDS 3:125-133.
52. Kalergis, A. M., and J. V. Ravetch. 2002. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J. Exp. Med. 195:1653-1659.
53. Keele, B. F., E. E. Giorgi, J. F. Salazar-Gonzalez, J. M. Decker, K. T. Pham, M. G. Salazar, C. Sun, T. Grayson, S. Wang, H. Li, X. Wei, C. Jiang, J. L. Kirchherr, F. Gao, J. A. Anderson, L.-H. Ping, R. Swanstrom, G. D. Tomaras, W. A. Blattner, P. A. Goepfert, J. M. Kilby, M. S. Saag, E. L. Delwart, M. P. Busch, M. S. Cohen, D. C. Montefiori, B. F. Haynes, B. Gaschen, G. S. Athreya, H. Y. Lee, N. Wood, C. Seoighe, A. S. Perelson, T. Bhattacharya, B. T. Korber, B. H. Hahn, and G. M. Shaw. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 105:7552-7557.
54. Klein, J. S., P. N. P. Gnanapragasam, R. P. Galimidi, C. P. Foglesong, A. P. West, Jr., and P. J. Bjorkman. 2009. Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proc. Natl. Acad. Sci. USA 106:7385-7390.
55. Kuster, H., H. Thompson, and J. P. Kinet. 1990. Characterization and expression of the gene for the human Fc receptor γ subunit. Definition of a new gene family. J. Biol. Chem. 265:6448-6452.
56. Kyogoku, C., N. Tsuchiya, K. Matsuta, and K. Tokunaga. 2002. Studies on the association of Fcγ receptor IIA, IIB, IIIA and IIIB polymorphisms with rheumatoid arthritis in the Japanese: evidence for a genetic interaction between HLA-DRB1 and FCGR3A. Genes Immun. 3:488-493.
57. Lambotte, O., Y. Taoufik, M. G. de Goer, C. Wallon, C. Goujard, and J. F. Delfraissy. 2000. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 23:114-119.
58. Laurence, J., A. Saunders, E. Early, and J. E. Salmon. 1990. Human immunodeficiency virus infection of monocytes: relationship to Fcγ receptors and antibody-dependent viral enhancement. Immunology 70:338-343.
59. Lehrnbecher, T., C. B. Foster, S. Zhu, S. F. Leitman, L. R. Goldin, K. Huppi, and S. J. Chanock. 1999. Variant genotypes of the low-affinity Fcγ receptors in two control populations and a review of low-affinity Fcγ receptor polymorphisms in control and disease populations. Blood 94:4220-4232.
60. Li, M., F. Gao, J. R. Mascola, L. Stamatatos, V. R. Polonis, M. Koutsoukos, G. Voss, P. Goepfert, P. Gilbert, K. M. Greene, M. Bilska, D. L. Kothe, J. F. Salazar-Gonzalez, X. Wei, J. M. Decker, B. H. Hahn, and D. C. Montefiori. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79:10108-10125.
61. Li, M., J. F. Salazar-Gonzalez, C. A. Derdeyn, L. Morris, C. Williamson, J. E. Robinson, J. M. Decker, Y. Li, M. G. Salazar, V. R. Polonis, K. Mlisana, S. A. Karim, K. Hong, K. M. Greene, M. Bilska, J. Zhou, S. Allen, E. Chomba, J. Mulenga, C. Vwalika, F. Gao, M. Zhang, B. T. M. Korber, E. Hunter, B. H. Hahn, and D. C. Montefiori. 2006. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in southern Africa. J. Virol. 80:11776-11790.
62. + T-cell line expresses functional CD64 (FcγRI), CD32 (FcγRII), and CD16 (FcγRIII) receptors but these do not enhance the infectivity of HIV-1-IgG complexes. Immunology 90:109-114.
63. Montefiori, D. C. 1997. Role of complement and Fc receptors in the pathogenesis of HIV-1 infection. Springer Semin. Immunopathol. 18:371-390.
64. Montero, M., N. E. van Houten, X. Wang, and J. K. Scott. 2008. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol. Mol. Biol. Rev. 72:54-84.
65. Naldini, L., U. Blomer, P. Gallay, D. Ory, R. Mulligan, F. H. Gage, I. M. Verma, and D. Trono. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-267.
66. Nimmerjahn, F., and J. V. Ravetch. 2007. Antibodies, Fc receptors and cancer. Curr. Opin. Immunol. 19:239-245.
67. Nimmerjahn, F., and J. V. Ravetch. 2005. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310:1510-1512.
68. Nimmerjahn, F., and J. V. Ravetch. 2008. Fcγ receptors as regulators of immune responses. Nat. Rev. Immunol. 8:34-47.
69. Nimmerjahn, F., and J. V. Ravetch. 2006. Fcγ receptors: old friends and new family members. Immunity 24:19-28.
70. Ofek, G., M. Tang, A. Sambor, H. Katinger, J. R. Mascola, R. Wyatt, and P. D. Kwong. 2004. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78:10724-10737.
71. Pantophlet, R., E. Ollmann Saphire, P. Poignard, P. W. H. I. Parren, I. A. Wilson, and D. R. Burton. 2003. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J. Virol. 77:642-658.
72. Parren, P. W. H. I., P. A. M. Warmerdam, L. C. M. Boeije, J. Arts, N. A. C. Westerdaal, A. Vlug, P. J. A. Capel, L. A. Aarden, and J. G. J. van de Winkel. 1992. On the interaction of IgG subclasses with the low affinity FcγRIIa (CD32) on human monocytes, neutrophils, and platelets. J. Clin. Investig. 90:1537-1546.
73. Patterson, S., A. Rae, N. Hockey, J. Gilmore, and F. Gotch. 2001. Plasmacytoid dendritic cells are highly susceptible to human immunodeficiency virus type 1 infection and release infectious virus. J. Virol. 75:6710-6713.
74. Platt, E. J., K. Wehrly, S. E. Kuhmann, B. Chesebro, and D. Kabat. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72:2855-2864.
75. Porges, A. J., P. B. Redecha, R. Doebele, L. C. Pan, J. E. Salmon, and R. P. Kimberly. 1992. Novel Fcγ receptor I family gene products in human mononuclear cells. J. Clin. Investig. 90:2102-2109.
76. Pricop, L., P. Redecha, J. L. Teilaud, J. Frey, W. H. Fridman, C. Sautes-Fridman, and J. E. Salmon. 2001. Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines. J. Immunol. 166:531-537.
77. Ravetch, J. V., and S. Bolland. 2001. IgG Fc receptors. Annu. Rev. Immunol. 19:275-290.
78. Ravetch, J. V., and J. P. Kinet. 1991. Fc receptors. Annu. Rev. Immunol. 9:457-492.
79. Ravetch, J. V., and L. L. Lanier. 2000. Immune inhibitory receptors. Science 290:84-89.
80. Ravetch, J. V., and B. Perussia. 1989. Alternative membrane forms of FcγRIII(CD16) on human natural killer cells and neutrophils: cell typespecific expression of two genes that differ in single nucleotide substitutions. J. Exp. Med. 170:481-497.
81. Redpath, S., T. E. Michaelson, I. Sandlie, and M. R. Clark. 1998. The influence of the hinge region length in binding of human IgG to human Fcγ receptors. Hum. Immunol. 59:720-727.
82. Regnault, A., D. Lankar, V. Lacabanne, A. Rodriguez, C. Thery, M. Rescigno, T. Saito, S. Verbeek, C. Bonnerot, P. Ricciardi-Castagnoli, and S. Amigorena. 1999. Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatability complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189:371-380.
83. Robinson, W. E., Jr., M. K. Gorny, J. Y. Xu, W. M. Mitchell, and S. Zolla-Pazner. 1991. Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J. Virol. 65:4169-4176.
84. Rodrigo, W. W. S. I., X. Jin, S. D. Blackley, R. C. Rose, and J. J. Schlesinger. 2006. Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human FcγRIA (CD64) or FcγRIIA (CD32). J. Virol. 80:10128-10138.
85. Sanders, R. W., M. Venturi, L. Schiffner, R. Kalyanaraman, H. Katinger, K. O. Lloyd, P. D. Kwong, and J. P. Moore. 2002. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 76:7293-7305.
86. Saphire, E. O., P. W. H. I. Parren, R. Pantophlet, M. B. Zwick, G. M. Morris, P. M. Rudd, R. A. Dwek, R. L. Stanfield, D. R. Burton, and I. A. Wilson. 2001. Crystal structure of a neutralizing human IgG against HIV-1: a template for vaccine design. Science 293:1155-1159.
87. Saphire, E. O., R. L. Stanfield, M. D. M. Crispin, P. W. H. I. Parren, P. M. Rudd, R. A. Dwek, D. R. Burton, and I. A. Wilson. 2002. Contrasting IgG structures reveal extreme asymmetry and flexibility. J. Mol. Biol. 319:9-18.
88. Sather, D. N., J. Armann, L. K. Ching, A. Mavrantoni, G. Sellhorn, Z. Caldwell, X. Yu, B. Wood, S. Self, S. Kalams, and L. Stamatatos. 2009. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83:757-769.
89. Scheid, J. F., H. Mouquet, N. Feldhahn, M. S. Seaman, K. Velinzon, J. Pietzsch, R. G. Ott, R. M. Anthony, H. Zebroski, A. Hurley, A. Phogat, B. Chakrabarti, Y. Li, M. Connors, F. Pereyra, B. D. Walker, H. Wardemann, D. Ho, R. T. Wyatt, J. R. Mascola, J. V. Ravetch, and M. C. Nussenzweig. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458:6360640.
90. Shen, R., H. E. Richter, R. H. Clements, L. Novak, K. Huff, D. Bimczok, S. Sankara-Walters, S. Dandekar, P. R. Clapham, L. E. Smythies, and P. D. Smith. 2009. Macrophages in vaginal but not intestinal mucosa are monocyte-like and permissive to human immunodeficiency virus type 1 infection. J. Virol. 83:3258-3267.
91. Spira, A. I., P. A. Marx, B. K. Patterson, J. Mahoney, R. A. Koup, S. M. Wolinsky, and D. D. Ho. 1996. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunode-ficiency virus into rhesus macaques. J. Exp. Med. 183:215-225.
92. Sullivan, K. E., A. F. Jawad, L. M. Piliero, N. Kim, X. Luan, D. Goldman, and M. Petri. 2003. Analysis of polymorphisms affecting immune complex handling in systemic lupus erythematosus. Rheumatology 42:446-452.
93. Sun, Z. Y. J., K. J. Oh, M. Kim, J. Yu, V. Brusic, L. Song, Z. Qiao, J. H. Wang, G. Wagner, and E. L. Reinherz. 2008. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 28:52-63.
94. Takeda, A., C. U. Tuazon, and F. A. Ennis. 1988. Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 242:580-583.
95. Trapp, S., S. G. Turville, and M. Robbian. 2006. Slamming the door on unwanted guests: why preemptive strikes at the mucosa may be the best strategy against HIV. J. Leukoc. Biol. 80:1076-1083.
96. Trischmann, H., D. Davis, and P. J. Lachmann. 1995. Lymphocytic strains of HIV-1 when complexed with enhancing antibodies can infect macrophages via Fcγ RIII, independently of CD4. AIDS Res. Hum. Retroviruses 11:343-352.
97. Trkola, A., M. Purtscher, T. Muster, C. Ballaun, A. Buchacher, N. Sullivan, K. Srinivasan, J. Sodroski, J. P. Moore, and H. Katinger. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1100-1108.
98. + effector cells armed in vivo with cytophilic antibody. J. Immunol. 142:1177-1182.
99. Tyler, D. S., S. D. Stanley, S. Zolla-Pazner, M. K. Gorny, P. P. Shadduck, A. J. Langlois, T. J. Matthews, D. P. Bolognesi, T. J. Palker, and K. J. Weinhold. 1990. Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J. Immunol. 145:3276-3282.
100. Vance, B. A., T. W. Huizinga, K. Wardwell, and P. M. Guyre. 1993. Binding of monomeric human IgG defines an expression polymorphism of Fcγ RIII on large granular lymphocyte/natural killer cells. J. Immunol. 151:6429-6439.
101. Van der Pol, W. L., M. D. Jansen, W. J. Sluiter, B. van de Sluis, F. G. Leppers-van de Straat, T. Kobayashi, R. G. Westendorp, T. W. Huizinga, and J. G. van de Winkel. 2003. Evidence for non-random distribution of Fcγ receptor genotype combinations. Immunogenetics 55:240-246.
102. Warmerdam, P. A., J. G. van de Winkel, A. Vlug, N. A. Westerdaal, and P. J. Capel. 1991. A single amino acid in the second Ig-like domain of the human Fcγ receptor II is critical for human IgG2 binding. J. Immunol. 147:1338-1343.
103. Wei, X., J. M. Decker, H. Liu, Z. Zhang, R. B. Arani, J. M. Kilby, M. S. Saag, X. Wu, G. M. Shaw, and J. C. Kappes. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
104. Wei, X., J. M. Decker, S. Wang, H. Hui, J. C. Kappes, X. Wu, J. F. Salazar-Gonzalez, M. G. Salazar, J. M. Kilby, M. S. Saag, N. L. Komarova, M. A. Nowak, B. H. Hahn, P. D. Kwong, and G. M. Shaw. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312.
105. Woof, J. M., and D. R. Burton. 2004. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat. Rev. 4:1-11.
106. Wyatt, R., and J. Sodroski. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280:1884-1888.
107. Xu, J. Y., M. K. Gorny, T. Palker, S. Karwowska, and S. Zolla-Pazner. 1991. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J. Virol. 65:4832-4838.
108. Yuste, E., H. B. Sanford, J. Carmody, J. Bixby, S. Little, M. B. Zwick, T. Greenough, D. R. Burton, D. D. Richman, R. C. Desrosiers, and W. E. Johnson. 2006. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma. J. Virol. 80:3030-3041.
109. + monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J. Virol. 76:707-716.
110. Zwick, M. B., A. F. Labrijn, M. Wang, C. Spenlehauer, E. O. Saphire, J. M. Binley, J. P. Moore, G. Stiegler, H. Katinger, D. R. Burton, and P. W. H. I. Parren. 2001. Broadly neutralizing antibodies targeted to the membraneproximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75:10892-10905.